Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL217886 | 0.93 | KDM4E (0.31) | KDM4EALDH1A1HPGDHSD17B10GABRA1 | |
| SCHEMBL12766214 | 0.92 | KDM4E (0.33) | KDM4EALDH1A1HPGDHSD17B10GABRA1 | |
| SCHEMBL217789 | 0.92 | KDM4E (0.33) | KDM4EALDH1A1HPGDHSD17B10GABRA1 | |
| SCHEMBL12766210 | 0.88 | KDM4E (0.32) | KDM4EALDH1A1HPGDHSD17B10GABRA1 | |
| SCHEMBL357717 | 0.88 | KDM4E (0.32) | KDM4EALDH1A1HPGDHSD17B10GABRA1 | |
| SCHEMBL2798558 | 0.87 | KDM4E (0.38) | KDM4EALDH1A1HPGDHSD17B10GABRA1 | |
| SCHEMBL5596447 | 0.84 | — | — | |
| SCHEMBL8351615 | 0.82 | KDM4E (0.35) | KDM4EALDH1A1HPGDHSD17B10GABRA1 | |
| SCHEMBL10598219 | 0.80 | KDM4E (0.32) | KDM4EALDH1A1HPGDHSD17B10GABRA1 | |
| SCHEMBL13199170 | 0.80 | KDM4E (0.32) | KDM4EALDH1A1HPGDHSD17B10GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312457-A1 | LOW-MIGRATION HINDERED PHENOL ANTIOXIDANT COMPOUND, PREPARATION METHOD AND COMPOSITION | TSENG, JERRY (TW) | 2023-10-05 | — | — | US | disclosed |
| US-7910664-B2 | 3 to 6 Polyalkylene oxide, polyacrylate, a polylactone, polylactam or derivative side-branches connected to a benzene central molecule by a methylene group, especially initiated by hexakis(bromomethyl)benzene; films for electronic devices; nucleophilic substitution; benzene ring formation; ATRP | LG CHEM, LTD. (KR) | 2011-03-22 | — | — | US | disclosed |
| US-20090238768-A1 | MULTIMERIC MAGNETIC RESONANCE CONTRAST AGENTS | AXELSSON OSKAR | 2009-09-24 | — | — | US | disclosed |
| US-20090238768-A1 | MULTIMERIC MAGNETIC RESONANCE CONTRAST AGENTS | AXELSSON OSKAR | 2009-09-24 | — | — | US | disclosed |
| US-20090238768-A1 | MULTIMERIC MAGNETIC RESONANCE CONTRAST AGENTS | AXELSSON OSKAR | 2009-09-24 | — | — | US | disclosed |
| US-20080161523-A1 | Radially multi-branched polymer and porous film using the same | CHEONG JAE HO | 2008-07-03 | — | — | US | disclosed |
| US-7297722-B2 | Radially multi-branched polymer and porous film using the same | LG CHEM, LTD. (KR) | 2007-11-20 | — | — | US | disclosed |
| WO-2007064227-A1 | MULTIMERIC MAGENTIC RESONANCE CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2007-06-07 | — | — | WO | disclosed |
| US-7208140-B2 | Trimeric macrocyclic substituted benzene derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-04-24 | — | — | US | disclosed |
| US-5795581-A | Controlled release of molecular components of dendrimer/bioactive complexes | SANDIA CORPORATION (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1996030002-A1 | CONTROLLED RELEASE OF MOLECULAR COMPONENTS COMPRISING THE USE OF FRAGMENTING AND EXPANDING MOLECULES | SANDIA CORPORATION (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161523-A1 | Radially multi-branched polymer and porous film using the same | PUF60, PARG, PARN | KDM4E 589/4885ALDH1A1 3356/4885HPGD 3825/4885 |
| US-20090238768-A1 | MULTIMERIC MAGNETIC RESONANCE CONTRAST AGENTS | MAG, MSR1, FABP7 | KDM4E 4443/4885ALDH1A1 2448/4885HPGD 481/4885 |
| US-20230312457-A1 | LOW-MIGRATION HINDERED PHENOL ANTIOXIDANT COMPOUND, PREPARATION METHOD AND COMPOSITION | COMT, CAT, GPX4 | KDM4E 2420/4885ALDH1A1 921/4885HPGD 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.